Skip to content

Nevoid Basal Cell Carcinomas in Gorlin Syndrome

Nevoid Basal Cell Carcinomas in Young People With Gorlin Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05898347
Enrollment
10
Registered
2023-06-12
Start date
2023-06-01
Completion date
2025-12-31
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma, Gorlin Syndrome

Keywords

Dermatoscopy

Brief summary

The overall aim of the project is to gain knowledge about the expected course of nevoid basal cell carcinomas and the usefulness of dermatoscopy in young individuals with Gorlin syndrome. Clinical experience and some case-reports suggest that nevoid basal cell carcinomas have an indolent course with slow growth and that they can sometimes regress. However, no systematic research has previously been performed. Increased knowledge about nevoid basal cell carcinomas and the use of dermatoscopy could be of great clinical value in the follow-up and treatment of individuals with nevoid basal cell carcinoma syndrome.

Interventions

OTHERActive surveillance

Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses. If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised.

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* The individual has Gorlin syndrome (clinically and/or genetically diagnosed) * The individual is minimum 6 years and maximum 17 years * The individual has at least three skin lesions clinically compatible with nevoid basal cell carcinomas

Exclusion criteria

* The patient has a psychiatric disorder not compatible with completion of the study examinations * The patient has received topical treatment (imiquimod, 5-fluorouracil, photodynamic therapy and/or cryotherapy) of nevoid basal cell carcinomas during the last three months

Design outcomes

Primary

MeasureTime frameDescription
Nevoid basal cell carcinoma size increaseTwo yearsLargest diameter (measured in millimeter) of nevoid basal cell carcinomas after two years surveillance compared to at baseline.
Dermatoscopy findingsTwo yearsDermatoscopy findings of nevoid basal cell carcinomas compared to nevoid basal cell carcinoma size increase.

Secondary

MeasureTime frameDescription
Nevoid basal cell carcinoma histologyTwo yearsHistological analysis, including immune histochemistry, of skin biopsies obtained from representative nevoid basal cell carcinomas.

Other

MeasureTime frameDescription
Clinical manifestations associated with nevoid basal cell carcinomasTwo yearsPresence of congenital anomalities and benign neoplasias (odontogenic keratocysts, other cysts, fibromas) in patients with nevoid basal cell carcinomas.
Mutation burden in nevoid basal cell carcinomas analyzed by next-generation sequencingTwo yearsNext-generation sequencing of DNA extracted from skin biopsies obtained from representative nevoid basal cell carcinomas, including genes described in skin carcinomas.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026